In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million on Aug 18 ’25. In the deal valued at $58.15 per share,13,081 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 207,004 shares worth roughly $12.85 million.
Then, Treco Douglas A bought 20,000 shares, generating $1,140,600 in total proceeds. Upon buying the shares at $57.03, the Director now owns 22,000 shares.
Before that, George Simeon bought 989,812 shares. CRISPR Therapeutics AG shares valued at $51,499,918 were divested by the Director at a price of $52.03 per share. As a result of the transaction, George Simeon now holds 1,730,179 shares, worth roughly $107.44 million.
JP Morgan initiated its CRISPR Therapeutics AG [CRSP] rating to an Overweight in a research note published on September 18, 2025; the price target was $70. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in mid February from “an In-line” to “an Outperform”. TD Cowen also remained covering CRSP and has increased its forecast on February 12, 2025 with a “Hold” recommendation from previously “Sell” rating. H.C. Wainwright started covering the stock on February 03, 2025. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -0.35% to $62.1. Over the last five days, the stock has gained 7.37%. CRISPR Therapeutics AG shares have risen nearly 25.23% since the year began. Nevertheless, the stocks have risen 57.77% over the past one year. While a 52-week high of $71.13 was reached on 07/21/25, a 52-week low of $30.04 was recorded on 04/07/25.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 60.34, which if violated will result in even more drops to 58.57. On the upside, there is a resistance level at 64.03. A further resistance level may holdings at 65.95.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-08-29, dropping by -1.37 million shares to a total of 22.07 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 23.45 million shares. There was a decline of -6.22%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 06, 2024 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $84.
